....just like there are lots of possible combo partners for Bavituximab, PI3K candidates still out there and looks like AZ digging their feet in further here...
-----------------------
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
Dec 17, 2015
Investment establishes in-house expertise in blood cancers and complements strategic use of immunotherapy in haematological malignancies and solid tumours ... ... Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “The investment is consistent with our focus on long-term growth and reflects the role targeted business development plays in our business model. We are boosting a key area in our comprehensive oncology portfolio with a late-stage, potential best-in-class medicine that could transform treatment for patients across a range of blood cancers.”
“Acalabrutinib provides us with a small molecule presence in blood cancers to complement our existing immunotherapy approach, in collaboration with Celgene in haematological malignancies. Furthermore, we look forward to working closely with the Acerta team and benefiting from the considerable clinical expertise they bring in this complex area of medicine.” ... ..
PI3K is one of the hottest pathways in biotech, and compounds that inhibit it have been the objects of some major deals. Roche AG acquired Piramed Ltd. for $175 million on the strength of its PI3K assets in 2008. More recently, Intellikine Inc. licensed its PI3K delta and gamma inhibitors to Infinity Pharmaceuticals Inc. for $488.5 million, and then later was acquired by Takeda Pharmaceutical Co. for $190 million up front, and $120 million in milestones. (See BioWorld Today, April 16, 2008, July 9, 2010, and Dec. 22, 2011.)
And, in fact, Gilead's PI3K compound, GS-1101, came from its acquisition of Calistoga Pharmaceuticals Inc. for $375 million. (See BioWorld Today, Feb. 23, 2011.)
Olivero AG; Genentech PI3K Research Team. Discovery of GDC-0032, a beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Presented at: AACR Annual Meeting; April 6-10, 2013; Washington, DC.
CP or Sunstar...or whomever wants to take a shot at this one: what do you think of this patent filed by Gilead just after our Sept 2012 sabotage and is it them just trying to gain some leverage, knowing PS Targeting is the key ?
Gilead just so happened to go after PI3K in Dec of 2012..hmmm